LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

Search

CRISPR Therapeutics AG

Closed

Sector Healthcare

47.93 3.59

Overview

Share price change

24h

Current

Min

47.22

Max

47.98

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+40.08 upside

Dividends

By Dow Jones

Next Earnings

19 Feb 2025

News Sentiment

By Acuity

50%

50%

162 / 392 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

CRISPR Therapeutics AG Chart

Past performance is not a reliable indicator of future results.

Related News

8 Dec 2023, 20:56 UTC

Major Market Movers

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

26 Sept 2024, 16:08 UTC

Earnings
Acquisitions, Mergers, Takeovers

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26 Sept 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

11 Apr 2024, 14:46 UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

8 Dec 2023, 18:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

8 Dec 2023, 16:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

8 Dec 2023, 16:21 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ

Peer Comparison

Price change

CRISPR Therapeutics AG Forecast

Price Target

By TipRanks

40.08% upside

12 Months Forecast

Average 67.07 USD  40.08%

High 100 USD

Low 30 USD

Based on 17 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

9

Buy

6

Hold

2

Sell

Technical Score

By Trading Central

47.25 / 52.52Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

162 / 392 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

$